Sequence and structure signatures of cancer mutation hotspots in protein kinases

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Dixit, Anshuman ^a   Yi, Lin ^a   Gowthaman, Ragul ^a   Torkamani, Ali ^b   Schork, Nicholas J ^b   Verkhivker, Gennady M ^a,c  

^a UNIVERSITY OF KANSAS   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE;

ARTICLE; BIOINFORMATICS; CARCINOGENICITY; CONTROLLED STUDY; DNA MODIFICATION; ENZYME ACTIVE SITE; GENE ACTIVATION; GENE ACTIVITY; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENE STRUCTURE; GENETIC CONSERVATION; GENETIC DATABASE; MOLECULAR MODEL; MUTATIONAL ANALYSIS; PROTEIN DOMAIN; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE; ALGORITHM; BIOLOGY; CATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MUTATION; NEOPLASM; NUCLEOTIDE SEQUENCE; PROTEIN CONFORMATION; PROTEIN TERTIARY STRUCTURE; STATISTICAL MODEL;

ALGORITHMS; CATALYSIS; COMPUTATIONAL BIOLOGY; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, MOLECULAR; MODELS, STATISTICAL; MOLECULAR CONFORMATION; MUTATION; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN CONFORMATION; PROTEIN KINASES; PROTEIN STRUCTURE, TERTIARY;

EID: 70449379413     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007485     Document Type: Article

References (140)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70.
2. International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437: 1299-1320.
3. International HapMap Consortium (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature 449: 851-861.
4. Eichler EE, Nickerson DA, Altshuler D, Bowcock AM, Brooks LD, et al. (2007) Completing the map of human genetic variation. Nature 447: 161-165.
5. Lander ES, Weinberg RA (2000) Genomics: journey to the center of biology. Science 287: 1777-1782.
6. Collins FS, Barker AD (2007) Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci Am 296: 50-57.
7. Hanks SK, Hunter T (1995) The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J 9: 576-596.
8. Hunter T, Plowman GD (1997) Review: the protein kinases of budding yeast: six score and more. Trends Biochem Sci 22: 18-22.
9. Hunter T (2000) Signaling - 2000 and beyond. Cell 100: 113-127.
10. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298: 1912-1934.
11. Manning G, Plowman GD, Hunter T, Sudarsanam S (2002) Evolution of protein kinase signaling from yeast to man. Trends Biochem Sci 10: 514-520.
12. Noble ME, Endicott JA, Johnson LN (2004) Protein kinase inhibitors: insights into drug design from structure. Science 303: 1800-1805.
13. Cherry M, DH (2004) Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights. Curr Med Chem 11: 663-673.
14. Cheetham GM (2004) Novel protein kinases and molecular mechanisms of autoinhibition. Curr Opin Struct Biol 14: 700-705.
15. Scheeff ED, Bourne PE (2005) Structural evolution of the protein kinase-like superfamily. PLoS Comput Biol 2005 1: e49.
16. Huse M, Kuriyan J (2002) The conformational plasticity of protein kinases. Cell 109: 275-282.
17. Nolen B, Taylor SS, Ghosh G (2004) Regulation of protein kinases. Controlling activity through activation segment conformation. Molecular Cell 15: 661-675.
18. Sridhar R, Hanson-Painton O, Cooper DR (2000) Protein kinases as therapeutic targets. Pharm Res 17: 1345-1353.
19. Madhusudan S, Ganesan TS (2004) Tyrosine kinase inhibitors in cancer therapy. Clin Biochem 37: 618-635.
20. Sawyers CL (2003) Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes and Dev 17: 2998-3010.
21. Sawyer TK (2004) Novel oncogenic protein kinase inhibitors for cancer therapy. Curr Med Chem Anticancer Agents 4: 449-455.
22. Knight ZA, Shokat KM (2005) Features of selective kinase inhibitors. Chem Biol 12: 621-637.
23. Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 2005 65(17): 7591-5.
24. Stephens P, Edkins S, Davies H, Greenman C, Cox C, et al. (2005) A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 37: 950-592.
25. Sjoblom T, Jones S, Wood LD, Parsons WD, Lin J (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274.
26. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, et al. (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39: 347-351.
27. blom T, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318: 1108-1113.
28. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
29. Jones S, Zhang X, Parsons DW, Lin JCH, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806.
30. Parsons DW, Jones S, Zhang X, Lin JCH, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
31. Kiemeney LA, Thorlacius S, Sulem P, Geller F, Aben KKH, et al. (2008) Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 40: 1307-1312.
32. Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, et al. (2009) Genomewide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 41: 324-328.
33. Weinstein BI (2002) Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297: 63-64.
34. Sharma SV, Settleman J (2007) Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21: 3214-3231.
35. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
36. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
37. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311.
38. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-1149.
39. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, et al. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11: 217-227.
40. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, et al. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105: 2070-2075.
41. Kumar A, Petri ET, Halmos B, Boggon TJ (2008) Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 26: 1742-1751.
42. Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, et al. (2007) Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res 67: 7987-7990.
43. Zhou T, Parillon L, Li F, Wang Y, Keats J, et al. (2007) Crystal structure of the T315I mutant of AbI kinase. Chem Biol Drug Des 70: 171-181.
44. Young MA, Gonfloni S, Superti-Furga G, Roux B, Kuriyan J (2001) Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell 105: 115-126.
45. Arora K, Brooks CL 3rd (2007) Large-scale allosteric conformational transitions of adenylate kinase appear to involve a population-shift mechanism. Proc Natl Acad Sci U S A 104: 18496-18501.
46. Ozkirimli E, Post CB (2006) Src kinase activation: A switched electrostatic network. Protein Sci 15: 1051-1062.
47. Ozkirimli E, Yadav SS, Miller WT, Post CB (2008) An electrostatic network and long-range regulation of Src kinases. Protein Sci 17: 1871-1880.
48. Banavali NK, Roux B (2007) Anatomy of a structural pathway for activation of the catalytic domain of Src kinase Hck. Proteins 67: 1096-1112.
49. Yang S, Roux B (2008) Src kinase conformational activation: Thermodynamics, pathways, and mechanisms. PLoS Comput Biol 4: e1000047.
50. Banavali NK, Roux B (2009) Flexibility and charge asymmetry in the activation loop of Src tyrosine kinases. Proteins 74: 378-389.
51. Yang S, Banavali NK, Roux B (2009) Mapping the conformational transition in Src activation by cumulating the information from multiple molecular dynamics trajectories. Proc Natl Acad Sci U S A 106: 3776-3781.
52. Berteotti A, Cavalli A, Branduardi D, Gervasio FL, Recanatini M, et al. (2009) Protein conformational transitions: the closure mechanism of a kinase explored by atomistic simulations. J Am Chem Soc 131: 244-250.
53. Shan Y, Seeliger MA, Eastwood MP, Frank F, Xu H, Jensen MØ, Dror RO, Kuriyan J, Shaw DE (2009) A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc Natl Acad Sci U S A 106: 139-144.
54. Zou J, Wang YD, Ma FX, Xiang ML, Shi B, Wei YQ, Yang SY (2008) Detailed conformational dynamics of juxtamembrane region and activation loop in c-Kit kinase activation process. Proteins 72: 323-332.
55. Papakyriakou A, Vourloumis D, Tzortzatou-Stathopoulou F, Karpusas M (2008) Conformational dynamics of the EGFR kinase domain reveals structural features involved in activation. Proteins 76: 375-386.
56. Dixit A, Torkamani A, Schork NJ, Verkhivker G (2009) Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. Biophys J 96: 858-874.
57. Dixit A, Verkhivker G (2009) Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations PLoS Comput Biol 5: e1000487.
58. Pellicena P, Kuriyan J (2006) Protein-protein interactions in the allosteric regulation of protein kinases. Curr Opin Struct Biol 16: 702-709.
59. Masterson LR, Mascioni A, Traaseth NJ, Taylor SS, Veglia G (2008) Allosteric cooperativity in protein kinase A. Proc Natl Acad Sci U S A 105: 506-511.
60. hling S, Scholl C, et al. (2008) Highthroughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 111: 4788-4796.
61. Tyner JW, Loriaux MM, Erickson H, Eide CA, Deininger J, et al. (2008) High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia. Leukemia 23: 406-409.
62. Tomasson MH, Xiang Z, Walgren R, Zhao Y, Kasai Y, et al. (2008) Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood 111: 4797-4808.
63. Fröhling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, et al. (2007) Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 12: 501-513.
64. Parmigiani G, Boca S, Lin J, Kinzler KW, Velculescu V, et al. (2009) Design and analysis issues in genome-wide somatic mutation studies of cancer. Genomics 93: 17-21.
65. Torkamani A, Verkhivker G, Schork NJ (2009) Cancer driver mutations in protein kinase genes. Cancer Lett 281: 117-127.
66. Krallinger M, Izarzugaza JMG, Rodriguez-Penagos C, Valencia A (2009) Extraction of human kinase mutations from literature, databases and genotyping studies BMC Bioinformatics 10(Suppl 8): S1.
67. Izarzugaza JM, Redfern OC, Orengo CA, Valencia A (2009) Cancer associated mutations are preferentially distributed in protein kinase functional sites. Proteins. In press.
68. Kaminker JS, Zhang Y, Waugh A, Haverty PM, Peters B, et al. (2007) Distinguishing cancer-associated missense mutations from common polymorphisms. Cancer Res 67: 465-473.
69. Kaminker JS, Zhang Y, Watanabe C, Zhang Z (2007) CanPredict: a computational tool for predicting cancer-associated missense mutations. Nucleic Acids Res (Web Server issue) 35: W595-598.
70. Torkamani A, Schork NJ (2007) Accurate prediction of deleterious protein kinase polymorphisms. Bioinformatics 23: 2918-2925.
71. Torkamani A, Schork NJ (2008) Prediction of cancer driver mutations in protein Kinases. Cancer Res. Cancer Res 68: 1675-1682.
72. Torkamani A, Kannan N, Taylor SS, Schork NJ (2008) Congenital disease SNPs target lineage specific structural elements in protein kinases. Proc Natl Acad Sci USA 105: 9011-9016.
73. Conde L, Vaquerizas JM, Santoyo J, Al-Shahrour F, Ruiz-Llorente S, et al. (2004) PupaSNP Finder: a web tool for finding SNPs with putative effect at transcriptional level. Nucleic Acids Res 32: W242-W248.
74. Sherry ST, Ward M, Sirotkin K (1999) dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res 9: 677-679.
75. Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, et al. (2008) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 36: D13-D21.
76. Rebholz-Schuhmann D, Marcel S, Albert S, Tolle R, Casari G, et al. (2004) Automatic extraction of mutations from Medline and cross-validation with OMIM. Nucleic Acids Res 32: 135-142.
77. Stenberg KA, Riikonen PT, Vihinen M (2000) KinMutBase, a database of human disease-causing protein kinase mutations. Nucleic Acids Res 28: 369-371.
78. Ortutay C, Väliaho J, Stenberg K, Vihinen M (2005) KinMutBase: a registry of disease-causing mutations in protein kinase domains. Hum Mutat 25: 435-442.
79. Väliaho J, Smith CI, Vihinen M (2006) BTKbase: the mutation database for X-linked agammaglobulinemia. Hum Mutat 27: 1209-1217.
80. Krawczak M, Ball EV, Fenton I, Stenson PD, Abeysinghe S, et al. (2000) Human gene mutation database - a biomedical information and research resource. Hum Mut 15: 45-51.
81. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, et al. (2003) Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 21: 577-581.
82. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, et al. (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 91: 355-358.
83. Niedner RH, Buzko OV, Haste NM, Taylor A, Gribskov M, et al. (2006) Protein kinase resource: an integrated environment for phosphorylation research. Proteins 63: 78-86.
84. Richardson CJ, Gao Q, Mitsopoulous C, Zvelebil M, Pearl LH, et al. (2009) MoKCa database-mutations of kinases in cancer. Nucleic Acids Res 37(Database issue): D824-31.
85. Kannan N, Neuwald AF (2005) Did protein kinase regulatory mechanisms evolve through elaboration of a simple structural component? J Mol Biol 351: 956-972.
86. Kornev AP, Haste NM, Taylor SS, Eyck LF (2006) Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci U S A 103: 17783-17788.
87. Kornev AP, Taylor SS, Ten Eyck LF (2008) A helix scaffold for the assembly of active protein kinases. Proc Natl Acad Sci U S A 105: 14377-14382.
88. Thomas PD, Kejariwal A (2004) Coding single-nucleotide polymorphisms associated with complex vs. Mendelian disease: evolutionary evidence for differences in molecular effects. Proc Natl Acad Sci U S A.101: 15398-15403.
89. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, et al. (2003) PANTHER: A library of protein families and subfamilies indexed by function, Genome Res. 13: 2129-2141.
90. Chiara F, Michieli P, Pugliese L, Comoglio PM (2003) Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity J Biol Chem 278: 29352-29358.
91. Lorenzato A, Olivero M, Patane S, Rosso E, Oliaro A, et al. (2002) Novel somatic mutations of the Met oncogene in human carcinoma Metastases activating cell motility and invasion, Cancer Res 62: 7025-7030.
92. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, et al. (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97: 2434-2439.
93. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, et al. (2001) Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 113: 983-988.
94. Ferrao PT, Gonda TJ, Ashman LK (2003) Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver. Leuk Res 27: 547-555.
95. Tan A, Westerman D, McArthur GA, Lynch K, Waring P, et al. (2006) Sensitive detection of KIT D816V in patients with mastocytosis. Clin Chem 52: 2250-2257.
96. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, et al. (2006) Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25: 3357-3364.
97. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, et al. (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92: 1736-1744.
98. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855-867.
99. Fu YN, Yeh CL, Cheng HH, Yang CH, Tsai SF, et al. (2008) EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy. Oncogene 27: 957-965.
100. Corbin AS, La Rosée P, Stoffregen EP, Druker BJ, Deininger MW (2003) Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101: 4611-4614.
101. Maritano D, Accornero P, Bonifaci N, Ponzetto C (2000) Two mutations affecting conserved residues in the Met receptor operate via different mechanisms. Oncogene 19: 1354-1361.
102. Gujral TS, Singh VK, Jia Z, Mulligan LM (2006) Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B. Cancer Res 66: 10741-10749.
103. Gujral TS, Mulligan LM (2006) Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2. Ann N Y Acad Sci 1073: 234-240.
104. Lai AZ, Gujral TS, Mulligan LM (2007) RET signaling in endocrine tumors: delving deeper into molecular mechanisms. Endocr Pathol 18: 57-67.
105. Cranston AN, Carniti C, Oakhill K, Andzelm ER, Stone EA, et al. (2006) RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. Cancer Res 66: 10179-10187.
106. Knowles PP, Rust JM, Kjaer S, Scott RP, Hanrahan S, et al. (2006) Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 281: 33577-33587.
107. Berthou S, Aebersold DM, Schmidt LS, Stroka D, Heigl C, et al. (2004) The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene 23: 5387-5393.
108. Morotti A, Mila S, Accornero P, Tagliabue E, Ponzetto C (2002) K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 21: 4885-4893.
109. Nakaigawa N, Weirich G, Schmidt L, Zbar B (2000) Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src. Oncogene 19: 2996-3002.
110. Miller M, Ginalski K, Lesyng B, Nakaigawa N, Schmidt L, et al. (2001) Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. Proteins 44: 32-43.
111. Griffith J, Black J, Faerman C, Swenson L, Wynn M, et al. (2004) The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 13: 169-178.
112. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, et al. (2004) Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279: 31655-31663.
113. Schiering N, Knapp S, Marconi M, Flocco MM, Cui J, et al. (2003) Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proc Natl Acad Sci U S A 100: 12654-12659.
114. Wang W, Marimuthu A, Tsai J, Kumar A, Krupka HI, et al. (2006) Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Proc Natl Acad Sci U S A 103: 3563-3568.
115. Foster R, Griffith R, Ferrao P, Ashman L (2004) Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. J Mol Graph Model 23: 139-152.
116. Torrent M, Rickert K, Pan BS, Sepp-Lorenzino L (2004) Analysis of the activating mutations within the activation loop of leukemia targets Flt-3 and c-Kit based on protein homology modeling. J Mol Graph Model 2004 23: 153-165.
117. Vendôme J, Letard S, Martin F, Svinarchuk F, Dubreuil P, et al. (2005) Molecular modeling of wild-type and D816V c-Kit inhibition based on ATPcompetitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem 48: 6194-201.
118. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, et al. (1997) Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA 94: 11445-11450.
119. Bardelli A, Longati P, Gramaglia D, Basilico C, Tamagnone L, et al. (1998) Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. Proc Natl Acad Sci USA 95: 14379-14383.
120. Boeckmann B, Bairoch A, Apweiler R, Blatter MC, Estreicher A, et al. (2003) The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res 31: 365-370.
121. Boutet E, Lieberherr D, Tognolli M, Schneider M, Bairoch A (2007) UniProtKB/Swiss-Prot. Methods Mol Biol 406: 89-112.
122. The UniProt Consortium The universal protein resource (UniProt) (2008) Nucleic Acids Res 36: D190-D195.
123. Kouranov A, Xie L, de la Cruz J, Chen L, Westbrook J, et al. (2006) The RCSB PDB information portal for structural genomics. Nucleic Acids Res 34(Database issue): D302-D305.
124. Zhang Y, Skolnick J (2005) TM-align: a protein structure alignment algorithm based on the TM-score. Nucleic Acids Res 33: 2302-2309.
125. Lawrence CE, Altschul SF, Boguski MS, Liu JS, Neuwald AF, et al. (1993) Detecting subtle sequence signals: a Gibbs sampling strategy for multiple alignment. Science 262: 208-214.
126. Neuwald AF, Liu JS, Lawrence CE (1995) Gibbs motif sampling: detection of bacterial outer membrane protein repeats. Protein Sci 4: 1618-1632.
127. Neuwald AF, Liu JS (2004) Gapped alignment of protein sequence motifs through Monte Carlo optimization of a hidden Markov model. BMC Bioinformatics 5: 157.
128. Kannan N, Taylor SS, Zhai Y, Venter JC, Manning G (2007) Structural and functional diversity of the microbial kinome. PLoS Biol. e17.
129. Pei J, Tang M, Grishin NV (2008) PROMALS3D web server for accurate multiple protein sequence and structure alignments Nucleic Acids Res 36(Web Server issue): W30-34.
130. Marti-Renom MA, Stuart A, Fiser A, Sa'nchez R, Melo A, et al. (2000) Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 29: 291-325.
131. Fiser A, Do RK, Sali A (2000) Modeling of loops in protein structures. Protein Science 9: 1753-1773.
132. Canutescu AA, Shelenkov AA, Dunbrack RL Jr (2003) A graph-theory algorithm for rapid protein side-chain prediction. Protein Sci 12: 2001-2014.
133. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al. (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26: 1781-1802.
134. MacKerell AD Jr, Bashford D, Bellott M, Dunbrack RL Jr, Evanseck JD, et al. (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102: 3586-3616.
135. MacKerell AD Jr, Banavali N, Foloppe N (2001) Development and current status of the CHARMM force field for nucleic acids. Biopolymers 56: 257-265.
136. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML, et al. (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79: 926-935.
137. Parthiban V, Gromiha MM, Schomburg D (2006) CUPSAT: prediction of protein stability upon point mutations. Nucleic Acids Res 34: W239-242.
138. Parthiban V, Gromiha MM, Abhinandan M, Schomburg D (2007) Computational modeling of protein mutant stability: analysis and optimization of statistical potentials and structural features reveal insights into prediction model development. BMC Struct Biol 7: 54.
139. Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L (2005) The FoldX web server: an online force field. Nucleic Acids Res 33: W382-388.
140. Guerois R, Nielsen JE, Serrano L (2002) Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol 320: 369-87.